173 related articles for article (PubMed ID: 32669512)
21. Enhancement of subarachnoid space during magnetic resonance imaging of endolymphatic hydrops: a case report.
Vajda M; Dědková J; Stříteská M; Jandura J; Ryška P
J Int Med Res; 2021 Jul; 49(7):3000605211029788. PubMed ID: 34250824
[TBL] [Abstract][Full Text] [Related]
22. Glymphatic Pathway of Gadolinium-Based Contrast Agents Through the Brain: Overlooked and Misinterpreted.
Deike-Hofmann K; Reuter J; Haase R; Paech D; Gnirs R; Bickelhaupt S; Forsting M; Heußel CP; Schlemmer HP; Radbruch A
Invest Radiol; 2019 Apr; 54(4):229-237. PubMed ID: 30480554
[TBL] [Abstract][Full Text] [Related]
23. Semi-quantitative evaluation of endolymphatic hydrops by bilateral intratympanic gadolinium-based contrast agent (GBCA) administration with MRI for Meniere's disease.
Fukuoka H; Tsukada K; Miyagawa M; Oguchi T; Takumi Y; Sugiura M; Ueda H; Kadoya M; Usami S
Acta Otolaryngol; 2010; 130(1):10-6. PubMed ID: 19363714
[TBL] [Abstract][Full Text] [Related]
24. Glymphatic MRI in idiopathic normal pressure hydrocephalus.
Ringstad G; Vatnehol SAS; Eide PK
Brain; 2017 Oct; 140(10):2691-2705. PubMed ID: 28969373
[TBL] [Abstract][Full Text] [Related]
25. Visualization of endolymphatic hydrops after administration of a standard dose of an intravenous gadolinium-based contrast agent.
Tanigawa T; Tamaki T; Yamamuro O; Tanaka H; Nonoyama H; Shiga A; Sato T; Ueda H
Acta Otolaryngol; 2011 Jun; 131(6):596-601. PubMed ID: 21351819
[TBL] [Abstract][Full Text] [Related]
26. The Glymphatic System: A Review of the Challenges in Visualizing its Structure and Function with MR Imaging.
Naganawa S; Taoka T
Magn Reson Med Sci; 2022 Mar; 21(1):182-194. PubMed ID: 33250472
[TBL] [Abstract][Full Text] [Related]
27. Relationship between Contrast Enhancement of the Perivascular Space in the Basal Ganglia and Endolymphatic Volume Ratio.
Ohashi T; Naganawa S; Katagiri T; Kuno K
Magn Reson Med Sci; 2018 Jan; 17(1):67-72. PubMed ID: 28592709
[TBL] [Abstract][Full Text] [Related]
28. Gadolinium Distribution in Cerebrospinal Fluid after Administration of a Gadolinium-based MR Contrast Agent in Humans.
Berger F; Kubik-Huch RA; Niemann T; Schmid HR; Poetzsch M; Froehlich JM; Beer JH; Thali MJ; Kraemer T
Radiology; 2018 Sep; 288(3):703-709. PubMed ID: 29737953
[TBL] [Abstract][Full Text] [Related]
29. Urinary Gadolinium Levels After Contrast-Enhanced MRI in Individuals with Normal Renal Function: a Pilot Study.
Alwasiyah D; Murphy C; Jannetto P; Hogg M; Beuhler MC
J Med Toxicol; 2019 Apr; 15(2):121-127. PubMed ID: 30543028
[TBL] [Abstract][Full Text] [Related]
30. The anterior eye chamber: entry of the natural excretion pathway of gadolinium contrast agents?
Deike-Hofmann K; von Lampe P; Schlemmer HP; Bechrakis N; Kleinschnitz C; Forsting M; Radbruch A
Eur Radiol; 2020 Aug; 30(8):4633-4640. PubMed ID: 32179994
[TBL] [Abstract][Full Text] [Related]
31. Effect of IV Administration of a Gadolinium-Based Contrast Agent on Breast Diffusion-Tensor Imaging.
Scaranelo AM; Degani H; Grobgeld D; Talbot N; Bodolai K; Furman-Haran E
AJR Am J Roentgenol; 2020 Oct; 215(4):1030-1036. PubMed ID: 32755227
[No Abstract] [Full Text] [Related]
32. Pediatric Brain: Repeated Exposure to Linear Gadolinium-based Contrast Material Is Associated with Increased Signal Intensity at Unenhanced T1-weighted MR Imaging.
Flood TF; Stence NV; Maloney JA; Mirsky DM
Radiology; 2017 Jan; 282(1):222-228. PubMed ID: 27467467
[TBL] [Abstract][Full Text] [Related]
33. Quantitative assessment of gadolinium deposition in dentate nucleus using quantitative susceptibility mapping.
Hinoda T; Fushimi Y; Okada T; Arakawa Y; Liu C; Yamamoto A; Okada T; Yoshida K; Miyamoto S; Togashi K
J Magn Reson Imaging; 2017 May; 45(5):1352-1358. PubMed ID: 27664936
[TBL] [Abstract][Full Text] [Related]
34. Preliminary experience with intravenous gadoxetate disodium as a craniospinal MR contrast agent.
McKinney AM; Gawande R; Pezeshk P; Truwit CL; Rykken JB
Eur J Radiol; 2015 Dec; 84(12):2539-47. PubMed ID: 26456308
[TBL] [Abstract][Full Text] [Related]
35. Evidence for bilateral endolymphatic hydrops in ipsilateral delayed endolymphatic hydrops: preliminary results from examination of five cases.
Nonoyama H; Tanigawa T; Tamaki T; Tanaka H; Yamamuro O; Ueda H
Acta Otolaryngol; 2014 Mar; 134(3):221-6. PubMed ID: 24279647
[TBL] [Abstract][Full Text] [Related]
36. Linear gadolinium-based contrast agent (gadodiamide and gadopentetate dimeglumine)-induced high signal intensity on unenhanced T
Ichikawa S; Omiya Y; Onishi H; Motosugi U
J Magn Reson Imaging; 2019 Apr; 49(4):1046-1052. PubMed ID: 30307671
[TBL] [Abstract][Full Text] [Related]
37. Acute adverse events in cardiac MR imaging with gadolinium-based contrast agents: results from the European Society of Cardiovascular Radiology (ESCR) MRCT Registry in 72,839 patients.
Uhlig J; Lücke C; Vliegenthart R; Loewe C; Grothoff M; Schuster A; Lurz P; Jacquier A; Francone M; Zapf A; Schülke C; ; May MS; Bremerich J; Lotz J; Gutberlet M;
Eur Radiol; 2019 Jul; 29(7):3686-3695. PubMed ID: 31041566
[TBL] [Abstract][Full Text] [Related]
38. Observed Deposition of Gadolinium in Bone Using a New Noninvasive in Vivo Biomedical Device: Results of a Small Pilot Feasibility Study.
Lord ML; Chettle DR; Gräfe JL; Noseworthy MD; McNeill FE
Radiology; 2018 Apr; 287(1):96-103. PubMed ID: 29237148
[TBL] [Abstract][Full Text] [Related]
39. Subsequent MRI of pediatric patients after an adverse reaction to Gadolinium-based contrast agents.
Hojreh A; Peyrl A; Bundalo A; Szepfalusi Z
PLoS One; 2020; 15(4):e0230781. PubMed ID: 32243440
[TBL] [Abstract][Full Text] [Related]
40. [Magnetic resonance imaging study of endolymphatic hydrops based on 3D-FLAIR sequence after single-dose intravenous gadolinium injection].
Lin Y; Wang ZY; Zhang ZR; Zheng X; Chen QH; Wang HJ; Hao XP; Li YX; Xian JF; Yang BT
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(5):333-337. PubMed ID: 30772972
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
